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Abstract
Analyses of stool from patients with acute watery diarrhea (AWD) using sensitive molecular
diagnostics have challenged whether fecal microbiological cultures have acceptably high
sensitivity for cholera diagnosis. If true, these findings imply that current estimates of the
global burden of cholera, which rely largely on culture-confirmation, may be underestimates.
We conducted a vaccine probe study to evaluate this possibility, assessing whether an
effective killed oral cholera vaccine (OCV) tested in a field trial in a cholera-endemic popula-
tion conferred protection against cholera culture-negative AWD, with the assumption that if
cultures are indeed insensitive, OCV protection in such cases should be detectable. We re-
analysed the data of a Phase III individually-randomized placebo-controlled efficacy trial of
killed OCVs conducted in Matlab, Bangladesh in 1985. We calculated the protective efficacy
(PE) of a killed whole cell-only (WC-only) OCV against first-episodes of cholera culture-neg-
ative AWD during two years of post-dosing follow-up. In secondary analyses, we evaluated
PE against cholera culture-negative AWD by age at vaccination, season of onset, and dis-
ease severity. In this trial 50,770 people received at least 2 complete doses of either WC-
only OCV or placebo, and 791 first episodes of AWD were reported during the follow-up
period, of which 365 were culture-positive for Vibrio cholerae O1. Of the 426 culture-nega-
tive AWD episodes, 215 occurred in the WC group and 211 occurred in the placebo group
(adjusted PE = -1.7%; 95%CI -23.0 to 13.9%, p = 0.859). No measurable PE of OCV was
observed against all or severe cholera culture-negative AWD when measured overall or by
age and season subgroups. In this OCV probe study we detected no vaccine protection
against AWD episodes for which fecal cultures were negative for Vibrio cholera O1. Results
from this setting suggest that fecal cultures from patients with AWD were highly sensitive for
cholera episodes that were etiologically attributable to this pathogen. Similar analyses of
other OCV randomized controlled trials are recommended to corroborate these findings.
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007179 March 14, 2019 1 / 9
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Im J, Islam M.T, Ahmmed F, Kim DR,
Chon Y, Zaman K, et al. (2019) Use of oral cholera
vaccine as a vaccine probe to determine the burden
of culture-negative cholera. PLoS Negl Trop Dis 13
(3): e0007179. https://doi.org/10.1371/journal.
pntd.0007179
Editor: Mathieu Picardeau, Institut Pasteur,
FRANCE
Received: October 17, 2018
Accepted: January 22, 2019
Published: March 14, 2019
Copyright: © 2019 Im et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in
any medium, provided the original author and
source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files. The data underlying the results
presented in the study were accessed through a
data sharing agreement between icddr,b and IVI.
To request access to the dataset used in this
analysis, please contact Armana Ahmed,
aahmed@icddrb.org.
Funding: The authors received no specific funding
for this study.
Author summary
Conventional microbiological culture has remained a relatively uncontested ‘gold stan-
dard’ for the diagnosis of cholera; however, emerging methods, including sensitive molec-
ular tests, challenge the current paradigm. One pivotal article demonstrated that culture
failed to detect cholera in one-third of the cholera-positive stool specimens confirmed by
other methods. This finding underscored the absence of a reliable reference test, further
complicated by newer tests outperforming the gold standard, leaving no suitable compar-
ator. In this study, we used oral cholera vaccine as a probe to investigate the reliability of
conventional culture as a diagnostic for cholera by measuring the effectiveness of the vac-
cine against cholera culture-negative acute watery diarrhea. We did not find any evidence
of protection, implying that the culture diagnostics used were reliable. The dynamics of
cholera transmission require a rapid response, and ascertaining the best rapid diagnostic
test for early detection of outbreaks will maximize the effectiveness of chronically limited
resources in high risk regions. As techniques advance, well-designed studies should be
implemented to systematically evaluate their merit against established methods, and
improved diagnostics, including rapid diagnostics and microbiological culture, should be
implemented into cholera control programs to reduce cholera transmission by creating a
better trigger for outbreak response.
Introduction
An estimated 2.9 million cases and 95 000 deaths occur each year due to cholera, caused pri-
marily by Vibrio cholerae (V. cholerae) O1, in endemic countries [1]. Until now, microbiolog-
ical cultures of stools have provided an accepted gold standard for diagnosing cholera in
patients with diarrhoea. Such cultures, particularly when done with alkaline peptone water
overnight enrichment, have been regarded as having very high diagnostic sensitivity, as well as
high diagnostic specificity. However, one influential paper has questioned the notion that con-
ventional fecal cultures have high sensitivity in diagnosing cholera [2].
A study conducted in Dhaka, Bangladesh, where cholera is endemic, reported that conven-
tional cultures identified V. cholerae 01 in stools in only 86 (66%) of 131 patients with clinically
suspected cholera identified during seasonal cholera outbreak who were positive by at least
one of a panel of diagnostic tests consisting of culture, multiplex PCR, and direct florescent
antibody tests [2]. The authors postulated that failure of culture methods to isolate V. cholerae
may be caused by bacterial inactivation by in vivo vibriolytic action of the phages and/or pre-
vention by host-induced mechanisms. In light of this conclusion, one implication is that the
current estimates of cholera disease burden that are based on culture-confirmed cholera may
be significant underestimates, and that a reassessment of past and recent cholera studies may
be needed to guide public health policy on cholera control measures in countries affected by
cholera.
We reasoned that if conventional fecal cultures for cholera do indeed have only moderate
diagnostic sensitivity, and if culture-negative cholera represented an appreciable fraction of
cases of acute, watery diarrhoea (AWD), the clinical syndrome of cholera, inactivated oral
cholera vaccines (OCVs), which are effective against culture-confirmed cholera [3–6], should
also exhibit detectable efficacy against cholera culture-negative AWD. In this sense, OCVs
could be used as a “probe” to evaluate the hypothesis that conventional diarrhoeal cultures are
an insensitive tool for the diagnosis of cholera. Herein, we report a re-analysis of a Phase 3 effi-
cacy trial of inactivated OCVs in Matlab, Bangladesh to evaluate this possibility.
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Results
In this trial 25 416 individuals were vaccinated with at least two doses of WC-only OCV, and
25 354 received at least two doses of placebo. Of the 50 770 people vaccinated with either WC-
only OCV or placebo, 791 first episodes of AWD from 786 patients during two years of follow-
up among which 365 were culture-positive for V. cholerae O1. Of the remaining 426 first epi-
sodes of culture-negative AWD, 215 (50.5%) occurred in recipients vaccinated with WC and
211 (49.5%) occurred in placebo recipients (Fig 1). A majority of the cases, 373 (87.6%)
occurred in individuals�5 years.
The overall occurrence of cholera culture-negative AWD did not differ statistically between
vaccinees and placebo recipients (adjusted PE = -1.7%; 95%CI -23.0 to 15.9%, p = 0.859)
(Table 1). In contrast the occurrence of cholera culture-positive AWD differed significantly
between the two groups (adjust PE = 51.7; 95% CI 39.9 to 61.2, p<0.001). When evaluating the
incidence of cholera culture-negative AWD by age subgroups and for cholera season, we again
failed to detect vaccine protection (Table 1). Finally, comparison of the incidence of severe
cholera culture-negative AWD in vaccinees versus placebo recipients failed to detect protective
efficacy of the OCV among all individuals (adjusted PE = -5.9%; 95%CI -34.0 to 16.3%,
p = 0.633), in different age subgroups, and in the cholera season (Table 1). To examine the pos-
sibility that specificity of cholera culture is different during the cholera and non-cholera sea-
son, a secondary analysis of children�5 years, for whom OCV was protective, during the
cholera season was conducted. Protection was also not detected under these conditions
(Table 1).
Discussion
Using OCV as a vaccine probe to detect culture-negative cholera during the first two years of
follow-up in a placebo-controlled, randomized trial in Matlab, we failed to detect OCV protec-
tion against all episodes of cholera culture-negative AWD, by age groups, for cholera season,
or by disease severity. In contrast, analyses showed 51.7% PE against culture confirmed cholera
in patients with AWD during the same interval of follow-up. Before discussing the interpreta-
tion of these findings, it is important to address the limitations of our study.
Only patients with diarrhoea severe enough to seek care at a health facility were captured in
the surveillance and included in the analysis, thus our findings may not pertain to less severe
cases of diarrhoea. Additionally, the study was conducted in a cholera endemic region where
people had pre-existing natural immunity to cholera and where cholera culture was performed
systematically, therefore the results of this study cannot be generalized for populations lacking
such immunity or where cholera culture diagnostics are not routine. However, one would
expect natural immunity to reduce the fecal shedding of ingested cholera vibrios, which would
tend to increase rather than decrease the diagnostic sensitivity of conventional cultures. Fur-
ther, this analysis was performed on the data collected over 3 decades ago which calls into
question present day generalizability. At the time of the trial, the prevailing circulating strains
were both El Tor and classical biotypes [7]. Since then, variants of the El Tor biotype have
emerged and become predominant in Bangladesh and many other cholera-endemic areas [8].
Finally, the validity of our conclusions hinges on the assumption that the OCV under study
was protective against culture-positive and culture-negative cholera. While there is no reason
to doubt this assumption, there is no direct evidence to support it.
On the other hand, our study had several strengths. The data were obtained from a prospec-
tive, placebo-controlled, individually randomized trial with comprehensive and systematic
surveillance for all episodes of diarrhoea in the study population, including fecal cultures at a
high-calibre diagnostic laboratory. Importantly, Matlab has a well-functioning demographic
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Fig 1. CONSORT diagram showing cholera culture-negative AWD episodes in trial participants through 2 years of follow-up.
https://doi.org/10.1371/journal.pntd.0007179.g001
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surveillance system, and patients in this study were accurately identified when they presented
for care at the heath facilities. Note that non-differential misclassification of patient identities
would have acted to diminish measured vaccine PE. Also arguing against such misclassifica-
tion was the concurrent demonstration of vaccine PE against culture-proven cholera. Addi-
tionally, our analysis only included registered individuals in the Matlab demographic
surveillance who had verifiably ingested vaccine or placebo. Finally, our study was adequately
powered to detect vaccine protection in cholera culture-negative AWD. As shown in Fig 1, the
Table 1. Incidence rates and protective effect of cholera culture-negative and -positive AWD and culture-negative severe AWD between vaccine and placebo groups
stratified by age group and cholera season.
WC OCV E. coli K12 Protective effect (PE)
n Cholera
negative
AWD
Person-
days
Incidence
per 100000
person-days
(95% CI)
n Cholera
negative
AWD
Person-
days
Incidence
per 100000
person-days
(95% CI)
Crude PE
(95%CI)
p-value Adj.� PE
(95% CI)
p-value
Cholera negative AWD
All ages 25416 215 18459505 1.2 (1.0, 1.3) 25354 211 18409762 1.2 (1.0, 1.3) -1.6 (-22.9,
16.0)
0.868 -1.7 (-23.0,
15.9)
0.859
<5 years 2864 32 2071704 1.5 (1.1, 2.2) 2772 21 2011696 1.0 (0.7, 1.6) -47.9
(-156.4,
14.7)
0.164 -47.9
(-156.4,
14.7)
0.164
�5 years 22552 183 16387801 1.1 (1.0, 1.3) 22582 190 16398066 1.2 (1.0, 1.3) 3.6 (-18.1,
21.3)
0.722 3.6 (-18.0,
21.3)
0.720
Cholera
season†
25416 81 18459505 0.4 (0.4, 0.6) 25354 92 18409762 0.5 (0.4, 0.6) 12.2 (-18.4,
34.9)
0.394 12.2 (-18.3,
34.9)
0.393
�5 years
and cholera
season†
22552 71 16387801 0.4 (0.34, 0.55) 22582 83 16398066 0.5 (0.41, 0.63) 14.4
(-17.5,37.6)
0.337 14.4
(-17.5,37.7)
0.336
Cholera negative severe AWD
All ages 25416 143 18490342 0.8 (0.7, 0.9) 25354 135 18449112 0.7 (0.6, 0.9) -5.7 (-33.7,
16.5)
0.645 -5.9 (-34.0,
16.3)
0.633
<5 years 2864 11 2080386 0.5 (0.3, 1.0) 2772 9 2018038 0.5 (0.2, 0.9) -18.6
(-186.1,
50.9)
0.705 -21.1
(-192.2,
49.8)
0.670
�5 years 22552 132 16409956 0.8 (0.7, 1.0) 22582 126 16431074 0.8 (0.6, 0.9) -4.9 (-33.9,
17.8)
0.701 -4.5 (-33.4,
18.1)
0.721
Cholera
season†
25416 49 18490342 0.3 (0.2, 0.4) 25354 52 18449112 0.3 (0.2, 0.4) 6.0 (-38.9,
36.4)
0.757 6.1 (-38.7,
36.4)
0.752
�5 years
and cholera
season†
22552 46 16409956 0.3 (0.21,0.38) 22582 50 16431074 0.30 (0.23,0.40) 7.9
(-37.5,38.3)
0.688 8.1
(-37.1,38.5)
0.678
Cholera positive AWD
All ages 25416 119 18497878 0.6 (0.5, 0.8) 25354 246 18416140 1.3 (1.2, 1.5) 51.8 (40.1,
61.3)
<0.001 51.7 (39.9,
61.2)
<0.001
<5 years 2864 48 2066164 2.3 (1.7, 3.1) 2772 49 2004104 2.4 (1.8, 3.3) 5.0 (-41.5,
36.2)
0.802 4.6 (-42.1,
35.9)
0.818
�5 years 22552 71 16431714 0.4 (0.3, 0.6) 22582 197 16412036 1.2 (1.0, 1.4) 64.0 (52.8,
72.6)
<0.001 63.9 (52.6,
72.5)
<0.001
Cholera
season†
25416 42 18497878 0.2 (0.2, 0.3) 25354 103 18416140 0.6 (0.5, 0.7) 59.4 (41.9,
71.6)
<0.001 59.2 (41.6,
71.5)
<0.001
WC: Killed whole cell-only vaccine; OCV: oral cholera vaccine; AWD: acute watery diarrhoea
CI: confidence interval
�All ages models are adjusted by religion, age, and sex; age-specific models are adjusted by religion and sex
†Cholera season defined as April-May and October-November
https://doi.org/10.1371/journal.pntd.0007179.t001
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surveillance detected a total of 791 first episodes of AWD, of which 365 were culture-positive
for cholera and 426 were culture-negative. If, as reported, the diagnostic sensitivity of conven-
tional fecal cultures for cholera is 66%, we would expect 189 (44%) of the 426 culture-negative
AWD cases to be cholera. For an OCV that was 51.7% protective against cholera in the same
setting and for the same duration of follow-up, a level of OCV protection against culture-nega-
tive AWD of 23% would have been detected. However, the upper boundary of the 95% confi-
dence interval for measured PE in the primary analysis (16%) excluded this value.
OCV: oral cholera vaccine; WC: whole-cell only vaccine; BS+WC: B-subunit whole-cell
vaccine; AWD: acute watery diarrhea
It is important to emphasize that our vaccine probe study was designed to evaluate whether
there was an appreciable fraction of cholera culture-negative cases of AWD in which patient
symptoms could be etiologically attributed to infection by V. cholerae O1. It is well docu-
mented that isolation of cholera vibrios from fecal specimens may not be sufficient per se to
incriminate the isolated vibrios as the cause of the patient’s diarrhoea [9]. In the earlier Bangla-
desh study that reported low diagnostic sensitivity of conventional microbiological cultures,
diagnoses of cholera were based on a panel of multiple diagnostic tests, including very sensitive
molecular methods [2]. It is possible that some of cholera culture-negative cholera cases desig-
nated as cholera by the alternative tests in this study were due to false positive isolations. How-
ever, it is also possible that in many of the cases where fecal shedding of V. cholerae O1 was
detected, vibrios may have been present but not the aetiology of symptoms.
The contention that conventional culture methods do not capture all cholera cases has
implications for cholera global burden estimates, which are already thought to be an underesti-
mation due to the incomplete diagnostic testing and reporting of cholera cases in many set-
tings. However, it is important to consider that identification of V. cholerae O1 in the stool
does not always confirm the etiologic role of the isolated organisms in causing a patient’s diar-
rheal symptoms, and that sophisticated diagnostic technologies, in some cases, may overstate
the fraction of diarrhoeal disease caused by cholera. While the findings of our study support
the use of conventional fecal cultures to diagnose cholera, contemporary studies in endemic as
well as non-endemic settings are needed to examine the validity of our findings.
Methods
Study site
The study was conducted in rural Bangladesh at Matlab, where icddr,b has been maintaining a
field research centre since 1963. Matlab is a low-lying riverine area that lies 55 km southeast of
Dhaka, the capital of Bangladesh, and has remained endemic for cholera. Since 1966 a Health
and Demographic Surveillance System (HDSS), which consists of regular cross-sectional cen-
suses and longitudinal registration of vital events, has been maintained in the study area [10].
Matlab OCV trial
The data were obtained from a Phase III efficacy study, an individually randomized, placebo-
controlled trial design, conducted in 1985 in which persons aged 2 to 15 years, and non-preg-
nant females older than 15 years were assigned to receive three oral doses of one of the follow-
ing agents: 1) cholera toxin B subunit killed whole-cell (BS-WC) cholera vaccine; 2) a vaccine
identical to BS-WC, but lacking BS (WC); or 3) a placebo consisting of killed Escherichia coli
K12 cells, as previously described [11]. Vaccination took place in 1985, and of the 124 035 per-
sons who were age-eligible for vaccination, 63 498 persons received all three doses of an
assigned study agent. Surveillance for diarrheal illnesses was undertaken at all three diarrheal
treatment centres serving the study population, where patients were assessed clinically and
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fecal specimens were collected for microbiological diagnosis of V. cholerae O1 with conven-
tional culture techniques, including overnight enrichment in alkaline peptone water.
OCV probe analysis
To evaluate whether the use of conventional fecal cultures to define cholera underestimated
the true incidence of cholera in the Matlab trial, we assessed whether recipients of at least two
complete doses of the WC-only OCV protected against AWD that was culture-negative for
cholera. We assumed that the protection by this vaccine against culture-negative cholera was
equivalent to the vaccine’s protection against culture-confirmed cholera. We chose not to eval-
uate protection by BS-WC in this analysis, because this vaccine, in contrast to WC-only vac-
cine, cross protects against heat labile toxin (LT)- producing enterotoxigenic Escherichia coli
diarrhoea, a cause of AWD for which conventional cholera cultures can be negative [12]. The
post-vaccination follow-up selected for this analysis was two years, an interval in which the
WC-only OCV was protective against culture-confirmed cholera.
For this analysis, we defined a diarrheal treatment visit as a visit in which the patient
reported three or more loose or liquid stools or one-to-two or an indeterminate number of
loose stools with at least two objective signs of dehydration on initial physical examination
(feeble or absent pulse, tenting of skin, sunken eyes, or dry mucous membranes). Diarrheal vis-
its were concatenated into diarrheal episodes when the date of onset of symptoms for one visit
was 7 or fewer days after the date of discharge for the previous visit. The onset of an episode
was the onset of first component visit of the episode. AWD episodes were diarrheal episodes
for which no stool with visible blood was reported. Cholera culture-negative AWD episodes
were those for which no fecal culture detected V. cholerae O1. Cholera culture-positive AWD
episodes required at least one culture during the episode that was positive for V. cholerae O1.
Such episodes were considered be severe if, at the time of any of the component visits for treat-
ment, an absent or feeble pulse was noted and at least one additional objective sign of dehydra-
tion was described (poor skin turgor, sunken eyes, or dry mucous membranes).
This vaccine probe analysis was designed to measure the difference in the disease incidence
of cholera culture-negative AWD between vaccine and placebo recipients. In the primary anal-
ysis we compared the overall occurrence of first episodes of cholera culture-negative AWD,
with onsets from 14–730 days after receipt of the second dose, in subjects who had received at
least two complete doses of killed WC-only vaccine or placebo, as earlier analyses had demon-
strated PE to be equivalent for recipients of two and three doses and the vaccine was demon-
strably protective against cholera during this follow-up interval [5]. In secondary analyses, we
evaluated vaccine protection against cholera culture-positive AWD, as well as cholera culture-
negative AWD by age at vaccination, season of onset, and disease severity. In these analyses,
which were undertaken to address the possibility that vaccine protection might be unmasked
when analysed for the older age group (�5 years), during the cholera season, or against severe
cholera, age was categorized as under five years versus five years and older; seasonality was
classified as cholera season (April-May and October-November) versus other; and cholera was
classified as severe or non-severe, as defined earlier.
We measured vaccine PE against first episodes of cholera culture-positive and cholera cul-
ture-negative AWD in Cox proportional hazard regression models, in which time to event was
measured in relation to receipt of the second dose, and deaths, out-migrations, and 730 days
after the second dose were right-censoring events. In the analysis of cholera season, the events
that occurred during the cholera season were counted in the numerator and the events that
occurred outside of the cholera season were censored at the time of event. In these models,
vaccination was expressed dichotomously as vaccine versus placebo. We controlled for
Oral cholera vaccine as a vaccine probe for culture-negative cholera
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007179 March 14, 2019 7 / 9
potentially confounding variables, i.e. the variables which were independently associated with
time to event at p value < .10 (two-tailed) in a backward selection algorithm. To evaluate het-
erogeneity of vaccine protection among different subgroups (age <5 and�5 years), interac-
tion terms between vaccination and subgroup variables in these models were evaluated. Before
including any variable as an independent variable in the model, we first determined whether
the proportional hazard assumption was fulfilled for the variable. There was no violation of the
assumption for variables included in this model. We estimated the hazard ratio (HR) for the
outcome by exponentiating the coefficient for the vaccination variable in the model; the 95%
confidence interval for the HR was estimated using the standard error of the coefficient. We
considered P < .05 (two-tailed) as the margin of statistical significance.
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